Saturday 17 October 2026
Export CMPX’s income statement to Excel — free account
Compass Therapeutics, Inc.
CMPX Healthcare Biotechnology
Compass Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $850,000.00. In the quarter to June 2026, EPS grew 7.14% and free cash flow fell 26.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.86
0.04
−4.44%
Follow CMPX
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 2.01 | 1.25 | 1.35 | 0.77 | 1.33 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 11.00 | 5.65 | 5.55 | 2.34 | 5.86 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 31 | 24 | 26 | 32 | 35 | — | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | — | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 1 | — | ||||
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 100.00 | — | |||||
| EBT | — | 0 | 0 | (35) | (29) | (82) | (39) | (42) | (49) | (66) | |||||
| EBT margin, % | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (5,808.82) | 0.00 | |||||
| Net income | — | 0 | 0 | (35) | (29) | (82) | (39) | (42) | (49) | (66) | |||||
| Depreciation | — | — | 2 | 2 | 2 | 2 | 1 | (1) | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | ||||
| Earnings | — | — | (0.73) | (5.19) | (0.96) | (1.31) | (0.37) | (0.33) | (0.36) | (0.42) | |||||
| Cash flow | — | — | (0.65) | (4.74) | (0.87) | (0.31) | (0.32) | (0.32) | (0.33) | (0.31) | |||||
| Capex | — | — | 0.00 | (0.07) | 0.00 | (0.02) | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | (0.65) | (4.81) | (0.87) | (0.34) | (0.32) | (0.32) | (0.33) | (0.31) | |||||
| Book value | — | 0.00 | (1.63) | (17.73) | 1.30 | 2.23 | 1.73 | 1.17 | 0.91 | 1.25 | |||||
| Shares, m | — | — | 52 | 7 | 31 | 63 | 105 | 127 | 137 | 158 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | — | ||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | — | |||||
| P/B | — | — | — | — | — | — | — | — | 1.59 | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | (1.74) | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (34) | (32) | (27) | (20) | (34) | (41) | (45) | (49) | ||||
| Capex | — | — | (2) | 0 | 0 | (1) | 0 | 0 | 0 | 0 | |||||
| Free cash flow | — | — | (34) | (32) | (27) | (21) | (34) | (41) | (45) | (49) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | 0 | (8) | 16 | 40 | 136 | 179 | 146 | 124 | 196 | ||||
| Total debt | — | — | 145 | 15 | 9 | 4 | 3 | — | — | — | |||||
| Net debt | — | — | 145 | (10) | (38) | (145) | (187) | (152) | (127) | (209) | |||||
| Shareholders’ equity | — | 0 | (85) | (119) | 40 | 140 | 182 | 149 | 125 | 197 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | 0.00 | (1,469.39) | (228.69) | (71.70) | (79.92) | (22.20) | (23.84) | (33.22) | (36.94) | ||||
| ROIC | — | 0.00 | (0.03) | 0.00 | (789.04) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | 100.72 | 0.08 | 58.55 | 75.01 | (91.30) | (24.38) | (25.74) | (36.07) | (41.29) | |||||
Negative figures in brackets.
Fiscal years to Dec 2024 · latest quarter Jun 2024
Charts ten years each
Compass Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ORMP Oramed Pharmaceuticals Inc. | $173.9M | 1.0× | — (loss-making) | +193.26% (above 0%: growing) | +493.75% (above 0%: growing) | +94.29% (above 0%: growing) | 0.65% | 0.00% | Compare |
| WHWK Whitehawk Therapeutics, Inc. | $173.3M | — (loss-making) | — (loss-making) | +33.48% (above 0%: growing) | n/m | +72.57% (above 0%: growing) | 89.36% | 0.00% | Compare |
| DTIL Precision BioSciences, Inc. | $170.3M | — (loss-making) | — (loss-making) | +37,272.41% (above 0%: growing) | n/m | +33.73% (above 0%: growing) | 100.00% | 0.00% | Compare |
| CHRS Coherus Oncology, Inc. | $165.3M | — (loss-making) | — (loss-making) | +39.53% (above 0%: growing) | n/m | −33.15% (below 0%: shrinking) | 70.35% | (225.98%) | Compare |
| IPHA Innate Pharma S.A. Sponsored ADR | $165.3M | — (loss-making) | — | +246.29% (above 0%: growing) | +106.08% (above 0%: growing) | −929.03% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| VRXA Veraxa Biotech AG | $162.5M | — | — | — | — | — | — | — | Compare |
| CMPX Compass Therapeutics, Inc. | $161.5M | — (loss-making) | — (loss-making) | — | n/m | −26.05% (below 0%: shrinking) | 100.00% | 0.00% | |
| ADAG Adagene Inc. Sponsored ADR | $161.1M | — (loss-making) | — (loss-making) | — | — | −11.08% (below 0%: shrinking) | — | — | Compare |
| MDWD MediWound Ltd. | $157.6M | — (loss-making) | — (loss-making) | −45.83% (below 0%: shrinking) | n/m | −49.90% (below 0%: shrinking) | 10.90% | (305.89%) | Compare |
| Median of peers | $165.3M | — | — | +116.40% | — | −11.08% | 40.63% | 0.00% |
Compass Therapeutics, Inc. (CMPX) key facts
- Compass Therapeutics, Inc. (CMPX) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Compass Therapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $850,000.00.
- As of October 16, 2026, CMPX traded at $0.86, a market capitalization of $161.5 million.
- Return on equity was −41.3% and debt-to-equity 0.00.
- Its Altman Z-score is 3.98 (safe zone) for fiscal 2024.